Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Squamous Cell Carcinoma of Head and Neck
Conditions
Keywords
Drug Therapy
Brief summary
In this study, adults with non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and squamous-cell carcinoma of the head and neck (SCCHN) will be treated with TAK-676 and pembrolizumab following radiotherapy. The main aims of this study are to check if people are improving after treatment with TAK-676, getting side effects from these combined treatments, and how much TAK-676 people with these cancers can receive without getting unacceptable side effects from it. Participants will receive radiotherapy, then at least 40 hours later will receive pembrolizumab followed by TAK-676 slowly through a vein (infusion). Participants will receive an infusion of pembrolizumab at the same dose every 3 weeks. Different small groups of participants will receive lower to higher doses of TAK-676 on specific days of a 21-day cycle. This study will be happening at sites in North America.
Detailed description
The drug being tested in this study is called TAK-676. This study will evaluate the safety, tolerability and preliminary antitumor activity of TAK-676 with pembrolizumab following radiation therapy in the treatment of advanced NSCLC, TNBC or SCCHN that has progressed on checkpoint inhibitors (CPIs) and will estimate the maximum tolerated dose (MTD) and determine the recommended phase 2 dose (RP2D) of this combination. The study will enroll approximately 65 participants. Participants will be assigned to dose escalating cohorts based on Bayesian Optimal Interval (BOIN) design. The starting dose of TAK-676 will be 0.2 mg and the subsequent dosing will be initiated based on the available safety and tolerability data from the previous cohort. This multi-center trial will be conducted in the United States. There will be many clinic visits. The number of visits will depend on the number of cycles of treatment. Participants will attend an end of treatment (EOT) visit 30 days after receiving their last dose of study drug or before the start of subsequent systemic anticancer therapy, whichever occurs first. They might continue to have check-ups every 12 weeks if they left the study for a reason apart from their cancer getting worse.
Interventions
DRUGPembrolizumab
IV infusion.
DRUGTAK-676
IV infusion.
RADIATIONImage-guided radiation therapy
Radiation therapy.
Sponsors
Takeda
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1. 2. Participants must have at least 2 measurable lesions (i.e. ≥10 mm longest diameter for extranodal lesions, ≥15 mm short axis for lymph nodes), with at least one inside and at least one other outside of the radiation field. The tumor outside the radiation field must be accessible for biopsy, and the participant must consent to tumor biopsy at screening and during treatment. 3. Participants must have pathologically confirmed (cytological diagnosis is adequate) advanced or metastatic NSCLC, TNBC, or SCCHN who have: * Received or been offered all established standard of care (SOC) treatment options for which they are eligible; and * Progressed on CPIs in a prior line of therapy. 4. Adequate bone marrow, renal and hepatic functions. 5. Left ventricular ejection fraction (LVEF) \>50%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan within 4 weeks before receiving the first dose of study drug. 6. Clinically significant toxic effects of previous therapy have recovered to Grade 1 (per NCI CTCAE, V5.0) or baseline, except for alopecia, Grade 2 peripheral neuropathy, and/or autoimmune endocrinopathies with stable endocrine replacement therapy.
Exclusion criteria
1. History of any serious cardiac or cerebrovascular conditions in the last 6 months, including uncontrolled congestive heart disease, unstable angina, myocardial infarction, hypertension greater than or equal to (≥) 160/100 millimeter of mercury (mmHg) in spite of optimal therapy, cardiac arrhythmias, pericardial effusion, cardiomyopathy, or symptomatic stroke. Chronic, stable atrial fibrillation on stable anticoagulation therapy, including low molecular weight heparin, will be allowed. 2. History of brain metastasis unless: * Clinically stable, (that is, treatment completed ≥4 weeks prior) following prior surgery, whole-brain radiation, or stereotactic radiosurgery, AND * Off corticosteroids. 3. Known history of uncontrolled autoimmune disorders, human immunodeficiency virus (HIV) infection, or other relevant congenital or acquired immunodeficiencies. 4. Chronic, active hepatitis (example, participants with known hepatitis B surface antigen seropositive and/or detectable hepatitis C virus \[HCV\]-ribonucleic acid \[RNA\]). 5. Treatment with any investigational products and systemic anticancer drugs (including vascular endothelial growth factor (VEGF) inhibitors), within 14 days or 5 half-lives, whichever is shorter, before Cycle 1 Day 1 (C1D1) of study drugs. 6. Prior radiation to lesions chosen for biopsy or response assessment. 7. Prior radiation to lesions other than those chosen for radiation therapy or biopsy in the current protocol within 4 weeks of C1D1 of study drug(s). 8. Use of systemic corticosteroids or other immunosuppressive therapy, concurrently or within 7 days of start of radiation therapy, with the following exceptions: * Topical, intranasal, inhaled, ocular, intra-articular, and/or other nonsystemic corticosteroids. * Physiological doses of replacement steroid therapy (example, for adrenal insufficiency). 9. Receipt of live attenuated vaccine (example, tuberculosis Bacillus Calmette-guerin \[BCG\] vaccine, oral polio vaccine, measles, rotavirus, yellow fiver) within 28 days of C1D1 of study drug(s). 10. Recipients of allogeneic or autologous stem cell transplantation or organ transplantation. 11. Ongoing Grade ≥2 infection or participants with Grade ≥2 fever of malignant origin. 12. Fridericia's corrected QT interval (QTcF) \>450 milliseconds (msec) (males) or \>475 msec (females) on a 12-lead electrocardiogram (ECG) during the screening period. 13. Grade ≥2 hypotension (that is, hypotension for which nonurgent intervention is required) at screening or during C1D1 pre-dose assessment. 14. Oxygen saturation less than (\<) 92% on room air at screening or during C1D1 predose assessment. 15. Use of medications that are known clinical organic anion transporting polypeptide 1B1 (OATP1B1) and/or OATP1B3 inhibitors, concurrently or within 14 days of C1D1 of study drugs. 16. Current smoker. 17. Vaping within 90 days of C1D1 of study drugs. 18. Current diagnosis of pneumonitis, interstitial lung disease, severe chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, other restrictive lung diseases, acute pulmonary embolism, or Grade ≥2 pleural effusion or ascites not controlled by tap or requiring indwelling catheters. 19. Treated with other stimulator of interferon genes (STING) agonists/antagonist and toll-like receptors agonists within the past 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | From first dose of study drug administration up to 32 months | AE: any untoward medical occurrence in participants administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAE: any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent. Severity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Grade 1: Mild (asymptomatic/mild symptoms; clinical/diagnostic observations only; intervention not indicated); Grade 2: Moderate (minimal, local/noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living \[ADL\]); Grade 3: Severe (severe/medically significant but not immediately life-threatening hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death related to AE. |
| Number of Participants With Dose-limiting Toxicities (DLTs) | During Cycle 1 (cycle length= 21 days) | A DLT was defined as any TEAE that occurred during Cycle 1 and was considered by investigator to be at least possibly related to TAK-676 in combination with pembrolizumab. TEAEs meeting DLT definitions occurring in later cycles were considered in the determination of recommended phase 2 dose (RP2D) of TAK-676. DLTs were assessed based on NCI CTCAE version 5.0. |
| Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | From first dose of study drug administration up to 32 months | TEAE: any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent. An SAE is defined as any untoward medical occurrence that: 1) results in death, 2) is life-threatening, 3) requires inpatient hospitalization or prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) leads to a congenital anomaly/birth defect in the offspring of the participant or 6) is a medically important event that satisfies any of the following: a) may require intervention to prevent items 1 through 5 above. b) may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization |
| Number of Participants With One or More TEAEs Leading to Dose Modifications | From first dose of study drug administration up to 32 months | TEAE: Any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent. |
| Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | From first dose of study drug administration up to 32 months | TEAE: Any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | Up to 32 months | ORRnonirradiated was defined as the percentage of participants who achieve cCRnonirradiated or cPRnonirradiated in the tumor lesions lying outside of the radiation field as determined by the investigator according to modified itRECIST. CR for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to the nearest single decimal place. |
| Duration of Response (DOR) For Tumors Within the Radiation Field (DORirradiated) | Up to 32 months | DORirradiated for tumor lesions lying within radiation field: as time from the date of first documentation of a cPRirradiated or better to the date of first documentation of irradiated PD in those lesions for irradiated responders (cPRirradiated or better). PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Irradiated responders without documentation of irradiated PD were censored at the date of last response assessment that is irradiated SD or better. PD of Target Lesions: at least a 20% increase in sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment started or appearance of 1 or more new lesions. PD of Nontarget Lesions: unequivocal progression of existing non-target lesions. Evaluation was determined by the investigator according to modified itRECIST. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. |
| Duration of Response (DOR) For Tumors Outside the Radiation Field (DORnonirradiated) | Up to 32 months | DORnonirradiated for tumor lesions lying outside of the radiation field was defined as time from the date of first documentation of a cPRnonirradiated or better to the date of first documentation of nonirradiated PD in those lesions for nonirradiated responders (cPRnonirradiated or better). PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Nonirradiated responders without documentation of nonirradiated PD were censored at the date of last response assessment that is nonirradiated SD or better. Evaluation was determined by the investigator according to modified itRECIST. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. |
| Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | Up to 32 months | ORR was defined as the percentage of participants who achieved confirmed complete response (cCR) or confirmed partial response (cPR) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version1.1 (RECIST, V1.1). Complete Response (CR) for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 millimeter (mm) and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). Partial Response (PR) was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to nearest single decimal place. |
| Time to Response (TTR) For Tumors Outside the Radiation Field (TTR Nonirradiated) | Up to 32 months | TTR nonirradiated in the tumor lesions lying outside of the radiation field was defined as the time from the date of first dose administration to the date of first documented cPRnonirradiated or better during the study in response-evaluable population as determined by the investigator according to modified itRECIST. PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. |
| Number of Participants With Increase in T-Cell Infiltration in Tumor Evaluated by Immunohistochemistry | Up to approximately 32 months | The T-cell infiltration levels were calculated as a change from pre-treatment to post-treatment levels. Number of participants who expressed increase in T-cell infiltration levels between the pre-treatment and post-treatment tumor biopsies are reported. |
| Time to Response (TTR) For Tumors Within the Radiation Field (TTRirradiated) | Up to 32 months | TTRirradiated in the tumor lesions lying within the radiation field was defined as the time from the date of first dose administration to the date of first documented cPRirradiated or better as determined by the investigator according to modified itRECIST. PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. |
| Duration of Response (DOR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1 | Up to 32 months | DOR:time from 1st documentation of cPR/better to 1st documentation of progressive disease(PD) for responders(cPR or better).PR:at least 30% decrease in sum of LD of target lesions,with reference of baseline sum LD.2nd assessment confirming PR must have taken place at least 4 weeks after response of interest.PD of Target Lesions:at least 20% increase in sum of LD of target lesions,with reference of smallest sum LD recorded since treatment started/appearance of 1/more new lesions.PD of Nontarget Lesions:unequivocal progression of existing non-target lesions.Responders without documentation of PD were censored at last response assessment that was stable disease(SD) or better.SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,with reference of smallest sum LD since treatment started.Evaluation was determined by investigator according to RECIST, V1.1.2nd assessment confirming CR/PR must have taken place at least 4 weeks after response of interest. |
| Time to Response (TTR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1 | Up to 32 months | TTR was defined as the time from the date of first dose administration to the date of first documented cPR or better as determined by the investigator according to RECIST, V1.1. PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. |
| Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | Up to 32 months | ORR was defined as the percentage of participants who achieve cCR or cPR as determined by the investigator according to Modified itRECIST. CR for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to the nearest single decimal place. |
| Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | Up to 32 months | ORRirradiated was defined as the percentage of participants who achieve cCRirradiated or cPRirradiated in the tumor lesions lying within the radiation field as determined by the investigator according to modified itRECIST. CR for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to the nearest single decimal place. |
Countries
United States
Participant flow
Recruitment details
Participants took part in the study at 5 investigative sites in the United States from 09 September 2021 to 30 April 2024.
Pre-assignment details
Participants with a diagnosis of non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) or squamous-cell carcinoma of the head and neck (SCCHN) were enrolled to receive radiotherapy, pembrolizumab 200 milligram (mg), intravenous (IV) infusion and TAK-676 IV infusion.
Participants by arm
| Arm | Count |
|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 0.2 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 4 |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 0.4 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 2 |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 0.8 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 4 |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 1.6 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 3 |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 2.5 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 7 |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 3.5 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 6 |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg Participants received image-guided radiation therapy between Day -8 and Day -2. Participants then received pembrolizumab 200 mg, infusion, IV, once on Day 1 of Cycle 1 and then every 3 weeks in each 21-day treatment cycle, followed by dazostinag 5.0 mg infusion, IV, once on Days 1, 8, 15 in each 21-day treatment cycle until disease progression, intolerance to pembrolizumab or TAK-676 or withdrawal of consent, whichever occurred first. | 6 |
| Radiation Only Participants received radiation therapy with daily image guidance using a fractionated dose of 8 gray (Gy) × 3. | 2 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 |
|---|---|---|---|---|---|---|---|---|---|
| Overall Study | Completion of Follow-up Period and Assessments | 0 | 1 | 0 | 1 | 3 | 2 | 0 | 0 |
| Overall Study | Death | 0 | 0 | 1 | 1 | 1 | 2 | 1 | 2 |
| Overall Study | Initiation of Another Systemic Anticancer Treatment | 3 | 1 | 2 | 0 | 1 | 2 | 3 | 0 |
| Overall Study | Lost to Follow-up | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Overall Study | Progressive Disease | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Reason Not Specified | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Transfer to long term safety study, single-patient Investigational New Drug application, or similar | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Overall Study | Withdrawal by Subject | 0 | 0 | 0 | 0 | 2 | 0 | 1 | 0 |
Baseline characteristics
| Characteristic | Radiation + Pembrolizumab +Dazostinag 0.2 mg | Radiation + Pembrolizumab +Dazostinag 0.4 mg | Radiation + Pembrolizumab +Dazostinag 0.8 mg | Radiation + Pembrolizumab +Dazostinag 1.6 mg | Radiation + Pembrolizumab +Dazostinag 2.5 mg | Radiation + Pembrolizumab +Dazostinag 3.5 mg | Radiation + Pembrolizumab +Dazostinag 5.0 mg | Radiation Only | Total |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 50.3 years STANDARD_DEVIATION 12.5 | 65.5 years STANDARD_DEVIATION 6.36 | 55.0 years STANDARD_DEVIATION 9.2 | 59.7 years STANDARD_DEVIATION 11.06 | 66.3 years STANDARD_DEVIATION 16.18 | 62.0 years STANDARD_DEVIATION 12.38 | 56.8 years STANDARD_DEVIATION 10.7 | 73.0 years STANDARD_DEVIATION 7.07 | 60.4 years STANDARD_DEVIATION 12.56 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 3 Participants | 2 Participants | 4 Participants | 3 Participants | 7 Participants | 5 Participants | 5 Participants | 2 Participants | 31 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 5 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) White | 3 Participants | 2 Participants | 3 Participants | 1 Participants | 6 Participants | 4 Participants | 3 Participants | 2 Participants | 24 Participants |
| Sex: Female, Male Female | 2 Participants | 0 Participants | 1 Participants | 2 Participants | 3 Participants | 4 Participants | 3 Participants | 0 Participants | 15 Participants |
| Sex: Female, Male Male | 2 Participants | 2 Participants | 3 Participants | 1 Participants | 4 Participants | 2 Participants | 3 Participants | 2 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk |
|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 2 | 1 / 4 | 1 / 3 | 1 / 7 | 2 / 6 | 1 / 6 | 2 / 2 |
| other Total, other adverse events | 4 / 4 | 2 / 2 | 4 / 4 | 3 / 3 | 7 / 7 | 5 / 6 | 6 / 6 | 2 / 2 |
| serious Total, serious adverse events | 0 / 4 | 1 / 2 | 3 / 4 | 1 / 3 | 3 / 7 | 0 / 6 | 3 / 6 | 1 / 2 |
Outcome results
Primary
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity
AE: any untoward medical occurrence in participants administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. TEAE: any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent. Severity grade is defined by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0. Grade 1: Mild (asymptomatic/mild symptoms; clinical/diagnostic observations only; intervention not indicated); Grade 2: Moderate (minimal, local/noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living \[ADL\]); Grade 3: Severe (severe/medically significant but not immediately life-threatening hospitalization/prolongation of hospitalization indicated; disabling; limiting self-care ADL); Grade 4: Life-threatening consequences, urgent intervention indicated; Grade 5: Death related to AE.
Time frame: From first dose of study drug administration up to 32 months
Population: Safety Analysis Set included participants who received at least 1 dose of radiation.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 4 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 2 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 4 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 4 Participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 3 Participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 7 Participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 3 Participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 5 Participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 2 Participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 4 Participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 6 Participants |
| Radiation Only | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting one or More TEAEs | 2 Participants |
| Radiation Only | Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Based on TEAEs Severity | Number of Participants Reporting Any Grade 3 or Higher TEAEs | 1 Participants |
Primary
Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs)
TEAE: any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent. An SAE is defined as any untoward medical occurrence that: 1) results in death, 2) is life-threatening, 3) requires inpatient hospitalization or prolongation of existing hospitalization, 4) results in persistent or significant disability/incapacity, 5) leads to a congenital anomaly/birth defect in the offspring of the participant or 6) is a medically important event that satisfies any of the following: a) may require intervention to prevent items 1 through 5 above. b) may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization
Time frame: From first dose of study drug administration up to 32 months
Population: Safety Analysis Set included participants who received at least 1 dose of radiation.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 3 Participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 3 Participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 3 Participants |
| Radiation Only | Number of Participants Reporting One or More Treatment Emergent Serious Adverse Events (TESAEs) | 1 Participants |
Primary
Number of Participants With Dose-limiting Toxicities (DLTs)
A DLT was defined as any TEAE that occurred during Cycle 1 and was considered by investigator to be at least possibly related to TAK-676 in combination with pembrolizumab. TEAEs meeting DLT definitions occurring in later cycles were considered in the determination of recommended phase 2 dose (RP2D) of TAK-676. DLTs were assessed based on NCI CTCAE version 5.0.
Time frame: During Cycle 1 (cycle length= 21 days)
Population: The DLT-evaluable Analysis Set included participants who received all Cycle 1 doses of dazostinag, pembrolizumab and 3 doses of radiation without experiencing a DLT by the end of Cycle 1 follow-up and participants who received 3 doses of radiation, pembrolizumab, and the required dazostinag doses up until a DLT during Cycle 1.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants With Dose-limiting Toxicities (DLTs) | 0 Participants |
Primary
Number of Participants With One or More TEAEs Leading to Dose Modifications
TEAE: Any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent.
Time frame: From first dose of study drug administration up to 32 months
Population: Safety Analysis Set included participants who received at least 1 dose of radiation.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 2 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 3 Participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 4 Participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 3 Participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants With One or More TEAEs Leading to Dose Modifications | 4 Participants |
| Radiation Only | Number of Participants With One or More TEAEs Leading to Dose Modifications | 1 Participants |
Primary
Number of Participants With One or More TEAEs Leading to Treatment Discontinuation
TEAE: Any AE either reported for the first time or worsening of a pre-existing event after the first dose of study drug is considered treatment emergent.
Time frame: From first dose of study drug administration up to 32 months
Population: Safety Analysis Set included participants who received at least 1 dose of radiation.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 1 Participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 0 Participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 1 Participants |
| Radiation Only | Number of Participants With One or More TEAEs Leading to Treatment Discontinuation | 1 Participants |
Secondary
Duration of Response (DOR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1
DOR:time from 1st documentation of cPR/better to 1st documentation of progressive disease(PD) for responders(cPR or better).PR:at least 30% decrease in sum of LD of target lesions,with reference of baseline sum LD.2nd assessment confirming PR must have taken place at least 4 weeks after response of interest.PD of Target Lesions:at least 20% increase in sum of LD of target lesions,with reference of smallest sum LD recorded since treatment started/appearance of 1/more new lesions.PD of Nontarget Lesions:unequivocal progression of existing non-target lesions.Responders without documentation of PD were censored at last response assessment that was stable disease(SD) or better.SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD,with reference of smallest sum LD since treatment started.Evaluation was determined by investigator according to RECIST, V1.1.2nd assessment confirming CR/PR must have taken place at least 4 weeks after response of interest.
Time frame: Up to 32 months
Population: The response-evaluable analysis subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation. Overall number of participants analyzed signifies participants who had cCR or cPR. Responders without documentation of PD were censored at the date of the last response assessment that was SD or better.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Duration of Response (DOR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1 | 9.26 months |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Duration of Response (DOR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1 | NA months |
Secondary
Duration of Response (DOR) For Tumors Outside the Radiation Field (DORnonirradiated)
DORnonirradiated for tumor lesions lying outside of the radiation field was defined as time from the date of first documentation of a cPRnonirradiated or better to the date of first documentation of nonirradiated PD in those lesions for nonirradiated responders (cPRnonirradiated or better). PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Nonirradiated responders without documentation of nonirradiated PD were censored at the date of last response assessment that is nonirradiated SD or better. Evaluation was determined by the investigator according to modified itRECIST. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest.
Time frame: Up to 32 months
Population: The Response-evaluable Analysis Subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation. Overall number of participants analyzed signifies participants who had cCRnonirradiated or cPRnonirradiated. Responders without documentation of PD were censored at the date of the last response assessment that was SD or better.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Duration of Response (DOR) For Tumors Outside the Radiation Field (DORnonirradiated) | NA months |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Duration of Response (DOR) For Tumors Outside the Radiation Field (DORnonirradiated) | NA months |
Secondary
Duration of Response (DOR) For Tumors Within the Radiation Field (DORirradiated)
DORirradiated for tumor lesions lying within radiation field: as time from the date of first documentation of a cPRirradiated or better to the date of first documentation of irradiated PD in those lesions for irradiated responders (cPRirradiated or better). PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. Irradiated responders without documentation of irradiated PD were censored at the date of last response assessment that is irradiated SD or better. PD of Target Lesions: at least a 20% increase in sum of the LD of target lesions, taking as reference the smallest sum LD recorded since treatment started or appearance of 1 or more new lesions. PD of Nontarget Lesions: unequivocal progression of existing non-target lesions. Evaluation was determined by the investigator according to modified itRECIST. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest.
Time frame: Up to 32 months
Population: The Response-evaluable Analysis Subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation. Overall number of participants analyzed signifies participants who had cCRirradiated or cPRirradiated. Responders without documentation of PD were censored at the date of the last response assessment that was SD or better.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Duration of Response (DOR) For Tumors Within the Radiation Field (DORirradiated) | NA months |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Duration of Response (DOR) For Tumors Within the Radiation Field (DORirradiated) | NA months |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Duration of Response (DOR) For Tumors Within the Radiation Field (DORirradiated) | NA months |
Secondary
Number of Participants With Increase in T-Cell Infiltration in Tumor Evaluated by Immunohistochemistry
The T-cell infiltration levels were calculated as a change from pre-treatment to post-treatment levels. Number of participants who expressed increase in T-cell infiltration levels between the pre-treatment and post-treatment tumor biopsies are reported.
Time frame: Up to approximately 32 months
Population: Overall number of participants analyzed are the participants who had paired samples (both pre-treatment and post-treatment biopsy sample) available for analysis, participants who did not have paired samples were not evaluable for this outcome measure.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Number of Participants With Increase in T-Cell Infiltration in Tumor Evaluated by Immunohistochemistry | 1 participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Number of Participants With Increase in T-Cell Infiltration in Tumor Evaluated by Immunohistochemistry | 1 participants |
Secondary
Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST)
ORR was defined as the percentage of participants who achieve cCR or cPR as determined by the investigator according to Modified itRECIST. CR for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to the nearest single decimal place.
Time frame: Up to 32 months
Population: The response-evaluable analysis subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 posttreatment evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 14.3 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Overall Response Rate Assessed by Investigator as Per Modified Intratumoral Immunotherapy RECIST (Modified itRECIST) | 0 percentage of participants |
Secondary
Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated)
ORRnonirradiated was defined as the percentage of participants who achieve cCRnonirradiated or cPRnonirradiated in the tumor lesions lying outside of the radiation field as determined by the investigator according to modified itRECIST. CR for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to the nearest single decimal place.
Time frame: Up to 32 months
Population: The response-evaluable analysis subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 14.3 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Overall Response Rate For Tumors Outside the Radiation Field (ORRnonirradiated) | 25.0 percentage of participants |
Secondary
Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated)
ORRirradiated was defined as the percentage of participants who achieve cCRirradiated or cPRirradiated in the tumor lesions lying within the radiation field as determined by the investigator according to modified itRECIST. CR for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 mm and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to the nearest single decimal place.
Time frame: Up to 32 months
Population: The response-evaluable analysis subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 50.0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 14.3 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 16.7 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Overall Response Rate For Tumors Within the Radiation Field (ORRirradiated) | 0 percentage of participants |
Secondary
Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1
ORR was defined as the percentage of participants who achieved confirmed complete response (cCR) or confirmed partial response (cPR) as determined by the investigator according to Response Evaluation Criteria in Solid Tumors, Version1.1 (RECIST, V1.1). Complete Response (CR) for Target Lesions was defined as disappearance of all target lesions and any pathological lymph nodes (whether target or nontarget) must have reduction in short axis to \<10 millimeter (mm) and for Nontarget Lesions was defined as disappearance of all nontarget lesions and normalization of tumor marker level and all lymph nodes must be non-pathological in size (\<10 mm short axis). Partial Response (PR) was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest. Percentages were rounded off to nearest single decimal place.
Time frame: Up to 32 months
Population: The response-evaluable analysis subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.4 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 0.8 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 1.6 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 14.3 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 0 percentage of participants |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Overall Response Rate (ORR) Assessed by Investigator as Per RECIST v1.1 | 25.0 percentage of participants |
Secondary
Time to Response (TTR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1
TTR was defined as the time from the date of first dose administration to the date of first documented cPR or better as determined by the investigator according to RECIST, V1.1. PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest.
Time frame: Up to 32 months
Population: The Response-evaluable Analysis Subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation. Overall number of participants analyzed signifies participants who had cPR.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Time to Response (TTR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1 | 1.38 months |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Time to Response (TTR) For All Tumor Lesions Assessed by Investigator as Per RECIST v1.1 | 5.39 months |
Secondary
Time to Response (TTR) For Tumors Outside the Radiation Field (TTR Nonirradiated)
TTR nonirradiated in the tumor lesions lying outside of the radiation field was defined as the time from the date of first dose administration to the date of first documented cPRnonirradiated or better during the study in response-evaluable population as determined by the investigator according to modified itRECIST. PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest.
Time frame: Up to 32 months
Population: The Response-evaluable Analysis Subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation. Overall number of participants analyzed signifies participants who had cPRnonirradiated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Time to Response (TTR) For Tumors Outside the Radiation Field (TTR Nonirradiated) | 1.38 months |
| Radiation + Pembrolizumab +Dazostinag 5.0 mg | Time to Response (TTR) For Tumors Outside the Radiation Field (TTR Nonirradiated) | 5.39 months |
Secondary
Time to Response (TTR) For Tumors Within the Radiation Field (TTRirradiated)
TTRirradiated in the tumor lesions lying within the radiation field was defined as the time from the date of first dose administration to the date of first documented cPRirradiated or better as determined by the investigator according to modified itRECIST. PR was defined as at least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD. The second assessment confirming a CR or PR must have taken place at least 4 weeks after the response of interest.
Time frame: Up to 32 months
Population: The response-evaluable analysis subset, a subset of the comprehensive response-evaluable analysis set, included participants with measurable disease at baseline and at least 1 post-treatment evaluation. Overall number of participants analyzed signifies participants who had cPRirradiated.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Radiation + Pembrolizumab +Dazostinag 0.2 mg | Time to Response (TTR) For Tumors Within the Radiation Field (TTRirradiated) | 1.41 months |
| Radiation + Pembrolizumab +Dazostinag 2.5 mg | Time to Response (TTR) For Tumors Within the Radiation Field (TTRirradiated) | 3.45 months |
| Radiation + Pembrolizumab +Dazostinag 3.5 mg | Time to Response (TTR) For Tumors Within the Radiation Field (TTRirradiated) | 1.15 months |